tiprankstipranks
Elevance Health (MX:ELV)
:ELV
Mexico Market
ELV
Elevance Health
RESEARCH TOOLSreports

Elevance Health (ELV) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$7,562.01
▲(17.26% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $7,562.01 with a high forecast of $8,293.96 and a low forecast of $6,679.36. The average price target represents a 17.26% change from the last price of $6,449.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5146":"$5,146","5933":"$5,933","6720":"$6,720","7507":"$7,507","8294":"$8,294"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8293.95968664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7562.006413748001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6679.35687879,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5146,5933,6720,7507,8294],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6422.335,6566.306129741539,6710.277259483077,6854.2483892246155,6998.219518966154,7142.190648707692,7286.161778449231,7430.13290819077,7574.104037932308,7718.075167673846,7862.046297415385,8006.017427156923,8149.988556898462,{"y":8293.95968664,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6422.335,6510.00203182677,6597.669063653539,6685.336095480308,6773.003127307077,6860.670159133847,6948.337190960616,7036.0042227873855,7123.671254614154,7211.338286440924,7299.005318267693,7386.672350094463,7474.339381921232,{"y":7562.006413748001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6422.335,6442.105913753077,6461.876827506154,6481.647741259231,6501.418655012308,6521.189568765385,6540.9604825184615,6560.731396271539,6580.502310024615,6600.273223777693,6620.044137530769,6639.8150512838465,6659.585965036923,{"y":6679.35687879,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5695.204,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5922.852,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6187.614,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5655.196,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5911.459,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5951.97,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5540.853,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5147.244,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5478.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6714.228,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7114.521,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6422.335,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6422.335,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8,294Average Price Target$7,562Lowest Price Target$6,679
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$7,818.08→$8,157.99
Buy
26.50%
Upside
Reiterated
09/11/26
Elevance Health price target raised to $480 from $460 at BofAElevance Health price target raised to $480 from $460 at BofA
Barclays Analyst forecast on MX:ELV
Andrew Mok CFA
Barclays
Barclays
$7,767.09
Buy
20.44%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY) and Elevance Health (NYSE: ELV)
Bernstein Analyst forecast on MX:ELV
Lance Wilkes
Bernstein
Bernstein
$8,293.96
Buy
28.61%
Upside
Reiterated
09/09/26
Elevance Health (ELV) Receives a Buy from Bernstein
Argus Research Analyst forecast on MX:ELV
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Morgan Stanley Analyst forecast on MX:ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$6,866.31
Hold
6.47%
Upside
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on MX:ELV
Whit Mayo
Leerink Partners
Leerink Partners
$6,186.48→$6,713.35
Hold
4.10%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on MX:ELV
Ryan Langston
TD Cowen
TD Cowen
$7,903.06
Buy
22.55%
Upside
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on MX:ELV
David S Macdonald
Truist Financial
Truist Financial
$8,073.01
Buy
25.18%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on MX:ELV
David Windley
Jefferies
Jefferies
$6,645.37→$7,648.12
Buy
18.59%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on MX:ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$8,361.94→$8,039.02
Buy
24.66%
Upside
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Robert W. Baird Analyst forecast on MX:ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$5,625.62→$6,679.36
Hold
3.57%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on MX:ELV
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on MX:ELV
Ben Hendrix
RBC Capital
RBC Capital
$7,461.16→$7,206.23
Hold
11.74%
Upside
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on MX:ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$6,288.45→$6,713.35
Hold
4.10%
Upside
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on MX:ELV
Jason Cassorla
Guggenheim
Guggenheim
$6,781.33→$7,733.1
Buy
19.91%
Upside
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$7,818.08→$8,157.99
Buy
26.50%
Upside
Reiterated
09/11/26
Elevance Health price target raised to $480 from $460 at BofAElevance Health price target raised to $480 from $460 at BofA
Barclays Analyst forecast on MX:ELV
Andrew Mok CFA
Barclays
Barclays
$7,767.09
Buy
20.44%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY) and Elevance Health (NYSE: ELV)
Bernstein Analyst forecast on MX:ELV
Lance Wilkes
Bernstein
Bernstein
$8,293.96
Buy
28.61%
Upside
Reiterated
09/09/26
Elevance Health (ELV) Receives a Buy from Bernstein
Argus Research Analyst forecast on MX:ELV
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Morgan Stanley Analyst forecast on MX:ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$6,866.31
Hold
6.47%
Upside
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on MX:ELV
Whit Mayo
Leerink Partners
Leerink Partners
$6,186.48→$6,713.35
Hold
4.10%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on MX:ELV
Ryan Langston
TD Cowen
TD Cowen
$7,903.06
Buy
22.55%
Upside
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on MX:ELV
David S Macdonald
Truist Financial
Truist Financial
$8,073.01
Buy
25.18%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on MX:ELV
David Windley
Jefferies
Jefferies
$6,645.37→$7,648.12
Buy
18.59%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on MX:ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$8,361.94→$8,039.02
Buy
24.66%
Upside
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Robert W. Baird Analyst forecast on MX:ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$5,625.62→$6,679.36
Hold
3.57%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on MX:ELV
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on MX:ELV
Ben Hendrix
RBC Capital
RBC Capital
$7,461.16→$7,206.23
Hold
11.74%
Upside
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on MX:ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$6,288.45→$6,713.35
Hold
4.10%
Upside
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on MX:ELV
Jason Cassorla
Guggenheim
Guggenheim
$6,781.33→$7,733.1
Buy
19.91%
Upside
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
STOKStoke Therapeutics
AXGNAxoGen
JAZZJazz Pharmaceuticals
PTGXProtagonist Therapeutics
CABACabaletta Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
George HillDeutsche Bank
Success Rate
12/18 ratings generated profit
67%
Average Return
+3.65%
Copying George Hill's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.65% per trade.
1 Year
A.J. RiceUBS
Success Rate
24/30 ratings generated profit
80%
Average Return
+19.75%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.75% per trade.
2 Years
A.J. RiceUBS
Success Rate
27/30 ratings generated profit
90%
Average Return
+38.94%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +38.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
29
30
27
21
18
Hold
9
9
9
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
39
36
30
26
In the current month, ELV has received 18 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 7,562.01.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $79.01 with a range of $77.08 to $84.53. The previous quarter’s EPS was $126.20. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELV is $79.01 with a range of $77.08 to $84.53. The previous quarter’s EPS was $126.20. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $835.08B with a range of $809.62B to $863.95B. The previous quarter’s sales results were $855.04B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s sales forecast for ELV is $835.08B with a range of $809.62B to $863.95B. The previous quarter’s sales results were $855.04B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is MX:ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 7,562.01.
    What is MX:ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 17.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Elevance Health a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Elevance Health’s share price target?
            The average share price target for Elevance Health is 7,562.01. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $8,293.96 ,and the lowest forecast is $6,679.36. The average share price target represents 17.26% Increase from the current price of $6,449.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Elevance Health?
                To buy shares of MX:ELV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.